GERN — Geron Corporation

Geron Corporation (GERN) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Net Revenue: $48 million, consistent with expectations.
• Full Year 2025 Net Revenue: $184 million, significantly up from $76 million in 2024, marking Rytelo's first full year of commercialization.
• Total Operating Expenses (2025): Approximately $255 million, aligning with guidance of $250 million to $260 million.
• Gross-to-Net Deductions: Increased to 17.7% in 2025 from 14.5% in 2024, attributed to wider 340B utilization and expanded GPO contracting.
• Cash Position: Approximately $400 million as of December 31, 2025, down from $503 million in 2024, but with access to an additional $125 million through a loan amendment.

2. Strategic Updates and Business Highlights

• Geron has restructured to focus on becoming a commercially driven organization, enhancing its leadership and refining its commercial strategy.
• Rytelo's growth strategy includes increasing awareness among healthcare professionals and expanding research partnerships within the hematology community.
• The company is targeting approximately 8,000 second-line lower-risk MDS patients in the U.S., leveraging updated NCCN guidelines that favor Rytelo as a second-line treatment option.

3. Forward Guidance and Outlook

• 2026 Rytelo Net Revenue Guidance: Expected between $220 million and $240 million, with growth anticipated in the latter half of the year.
• 2026 Total Operating Expenses Guidance: Projected to be between $230 million and $240 million, reflecting a streamlined approach.
• Geron aims to maintain operational execution and patient delivery, with a focus on commercial growth and potential international expansion.

4. Bad News, Challenges, or Points of Concern

• The increase in gross-to-net deductions indicates potential pricing pressures as the business matures.
• The company is facing competitive pressures from existing therapies, particularly ESAs and the evolving treatment landscape with luspatercept.
• There is uncertainty regarding the European market, particularly concerning HTA processes and pricing negotiations, which could impact future revenue from international markets.

5. Notable Q&A Insights

• Management emphasized the importance of Q4's 9% demand growth as a positive indicator for future performance.
• There is a clear focus on expanding both the breadth (new prescribing accounts) and depth (repeat prescriptions) of Rytelo usage.
• The company sees a path to profitability but prioritizes investments in commercial strategies and clinical trials over immediate profitability.
• The management acknowledged the shift in treatment paradigms, with Rytelo positioned favorably as a second-line treatment following luspatercept, which is becoming more dominant in first-line settings.

Overall, Geron Corporation's Q4 2025 earnings call highlighted a year of significant revenue growth and strategic realignment, setting the stage for continued focus on Rytelo's commercialization and market penetration in 2026, despite facing competitive and operational challenges.